Royalty Pharma Overview

  • Founded
  • 1996
Founded
  • Status
  • Public
  • Employees
  • 66
Employees
  • Stock Symbol
  • RPRX
Stock Symbol
  • Investments
  • 39
  • Share Price
  • $39.52
  • (As of Friday Closing)

Royalty Pharma General Information

Description

Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.

Contact Information

Website
www.royaltypharma.com
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Other Pharmaceuticals and Biotechnology
Stock Exchange
NAS
Primary Office
  • 110 East 59th Street
  • Floor 33
  • New York, NY 10022
  • United States
+1 (212) 000-0000

Royalty Pharma Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Royalty Pharma Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$39.52 $39.78 $34.86 - $47.10 $17.4B 435M 2.1M $1.44

Royalty Pharma Financials Summary

In Thousands,
USD 		TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 25,700,880 26,106,932 27,852,217
Revenue 2,278,485 2,289,463 2,122,353 1,814,254
EBITDA 1,362,624 1,376,804 1,853,692 2,731,587
Net Income 602,370 619,728 975,040 2,348,535
Total Assets 17,378,888 17,515,865 16,020,286 12,449,895
Total Debt 7,101,138 7,096,070 5,816,584 6,238,122
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Royalty Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Royalty Pharma‘s full profile, request access.

Request a free trial

Royalty Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical ind
Pharmaceuticals
New York, NY
66 As of 2021
00.000
000000000 00.000

00000 &

incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ull
000000000000000
Kenilworth, NJ
00000 As of 0000
00000000

000000

re et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi u
000000000000000
New York, NY
00000 As of 0000
000000000-00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Royalty Pharma Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Merck & Co. Corporation Kenilworth, NJ 00000 00000000
000000 Corporation New York, NY 00000 000000000-00
You’re viewing 2 of 2 competitors. Get the full list »

Royalty Pharma Patents

  • 138

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 4

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Royalty Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
FR-3056234-B1 Rolling gear and / or person access control device to a predetermined zone Active 20-Sep-2016 0000000000
FR-3056234-A1 Device for controlling the access to the rolling machine and / or person to a predetermined zone Granted 20-Sep-2016 0000000000 0
FR-3056235-A1 Device for controlling the access to the rolling machine and / or person to a predetermined zone Pending 20-Sep-2016 0000000000
EP-3516120-B1 Device for controlling access of a wheeled vehicle and/or person to a predetermined area Active 20-Sep-2016 0000000000
EP-3516120-A1 Device for controlling access of a wheeled vehicle and/or person to a predetermined area Granted 20-Sep-2016 E01F13/044
To view Royalty Pharma’s complete patent history, request access »

Royalty Pharma Executive Team (16)

Name Title Board Seat Contact Info
Pablo Legorreta Chief Executive Officer & Chairman
Terrance Coyne Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
George Lloyd JD Executive Vice President & General Counsel, Legal
Jim Reddoch Ph.D Executive Vice President, Co-Head Research & Investments and Chief Scientific Officer
Marshall Urist MD Executive Vice President
You’re viewing 5 of 16 executive team members. Get the full list »

Royalty Pharma Board Members (13)

Name Representing Role Since
000000000 000000000 Royalty Pharma Board Member 000 0000
00000000000 0000 Self Executive Vice President & Vice Chairman 000 0000
00000 0000000 Self Board Member 000 0000
00000 00 00000 00.0 Self Board Member 000 0000
0000000 000000 Self Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Royalty Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Royalty Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Royalty Pharma‘s full profile, request access.

Request a free trial

Royalty Pharma Investments & Acquisitions (39)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 02-May-2022 00000 0000 00000 Drug Delivery
000000000000 07-Jan-2022 0000 Pharmaceuticals
00000000 0000 22-Nov-2021 0000 0000 Pharmaceuticals 00000 000
0000000000000 01-Apr-2021 000000000 00000 Other Healthcare Services 00000 000
Biohaven Pharmaceutical 07-Aug-2020 PIPE 00000 Drug Discovery
You’re viewing 5 of 39 investments and acquisitions. Get the full list »

Ready to get started?

Request a free trial

Royalty Pharma Subsidiaries (1)

Company Name Industry Location Founded
0000000 Pharmaceuticals
To view Royalty Pharma’s complete subsidiaries history, request access »

Royalty Pharma Exits (3)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000000 000000000 07-Aug-2020 0000 00000 Completed
  • 0000000 000000
00000000 000000000 19-Jun-2018 0000 0000 Completed
  • 0000000 000000
Cypress Bioscience 15-Dec-2010 Buyout/LBO 00000 Completed
  • 2 buyers
To view Royalty Pharma’s complete exits history, request access »